ArticleInternational urology and nephrology2021
Incidence of death from kidney diseases among cancer patients: a US population-based analysis.
Article in International urology and nephrology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 2 citations in OpenAlex.
- Erythropoietin mitigated thioacetamide-induced renal injury via JAK2/STAT5 and AMPK pathway.Scientific reports · 2023Article
- Protective effect of quercetin on kidney diseases: From chemistry to herbal medicines.Frontiers in pharmacology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe purpose of our study was to retrospectively analyze the characteristic of death from kidney diseases among cancer patients and to screen the risk factors associated with nephrotic death using data from the surveillance, epidemiology, and end results (SEER) database.
methodsThe information on cancer patients dying of kidney diseases was retrieved from the SEER database. Standardized mortality ratios (SMRs) were calculated using the US general population as reference. Univariate and multivariate Cox regression analyses were conducted to screen potential risk factors of death from kidney diseases.
resultsData of 7,167,808 patients diagnosed with malignant tumors between 2000 and 2016 were collected. Of these, 25,903 patients died of kidney diseases. Compared to the general population, cancer patients were at an elevated risk of nephrotic death with an SMR of 3.17, and this risk continues to increase in recent years. The majority of deaths from kidney diseases occur in patients > 45-year-old diagnosed with cancer of prostate, colorectum, and breast. Additionally, cancer patients with diagnosis in recent years, older age at diagnosis, black race, higher grade, and poorer disease stage were more likely to die of kidney diseases are at higher risk of nephrotic death compared to other cancer survivors.
conclusionThe risk of death from kidney diseases is increasing among cancer survivors recently. Nephrologists should be actively involved in certain facets of cancer treatment, and provide effective nephrology care, especially for elderly patients with black race, higher grade, and poorer disease stage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.